We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring

This study has been terminated.
(Feasibility issues.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01752231
First Posted: December 19, 2012
Last Update Posted: September 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
City of Hope Medical Center
  Purpose
This pilot clinical trial studies dynamic contrast enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing cancer. New diagnostic procedures, such as DCE-MRI may help find and diagnose cancer

Condition Intervention
Normal Volunteers Drug: MultiHance Procedure: dynamic contrast-enhanced magnetic resonance imaging

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring

Resource links provided by NLM:


Further study details as provided by City of Hope Medical Center:

Primary Outcome Measures:
  • Dynamic contrast-enhanced MRI (DCE-MRI) as a measure of tumor treatment response. [ Time Frame: 1 year ]
    Analysis of DCE-MRI data will be by semi-quantitative metrics such as the area under the curve (AUC), the slopes of contrast agent uptake and washout curves as well as peak contrast agent uptake. Alternatively quantitative metrics based upon pharmacokinetic modeling will be derived. The model is the 2-compartment Kety model from which volume transfer constants between compartments and volume of the tissue compartments can be calculated.


Enrollment: 1
Actual Study Start Date: July 23, 2013
Study Completion Date: August 29, 2017
Primary Completion Date: August 29, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DCE-MRI (dynamic contrast-enhanced MRI)
Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
Drug: MultiHance
Other Name: Gadobenate dimeglumine
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Undergo DCE-MRI using new pulse sequences
Other Name: DCE-MRI

Detailed Description:

PRIMARY OBJECTIVES:

I. Optimize and develop functional DCE-MRI pulse sequences, which involve the injection of MRI-visible contrast agents, for imaging in the head/neck, abdominal and pelvic regions.

II. Determine the ideal radiofrequency (RF) coil setup to maximize signal to noise ratio of the optimized pulse sequences.

III. Distill the findings of specific aims 1 and 2 into streamlined protocols that can be used in subsequent studies for cancer phenotyping and treatment monitoring in a quantitative manner.

IV. To establish a virtual reference image repository for future studies.

OUTLINE: Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All subjects are eligible except for the following special cases:

Exclusion Criteria:

  • Female subjects who are or may be pregnant will NOT be eligible.
  • The minimum age for all subjects is 18 years old. No subjects under the age of 18 shall be considered.
  • If subject has received an imaging contrast agent of any kind within the past 7 days, they shall not be included in the study.
  • Subjects for whom MRI is contraindicated as set forth by the City of Hope Department of Radiology. These include:

    • electrical implants such as cardiac pacemakers or perfusion pumps
    • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
    • ferromagnetic objects such as jewelry or metal clips in clothing
    • pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder
    • any greater than normal potential for cardiac arrest
    • any subject with known kidney insufficiency function as evidenced by an abnormal serum creatinine (normal = 0.6 - 1.5 mg/dL) from a blood test performed on the subject within the past 6 months of the study date.
    • Any subject with abnormal creatinine clearance (normal = 100-130 ml/min/1.73m2), as measured by a direct test or from plasma creatinine (14) levels shall be excluded.
  • Normal subjects with a history of severe claustrophobia will not be eligible.
  • For ease of recruiting and study management purposes, only subjects who can give consent in English shall be eligible for this study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01752231


Locations
United States, California
City of Hope Medical Center
Duarte, California, United States, 91010
Sponsors and Collaborators
City of Hope Medical Center
Investigators
Principal Investigator: Jinha Park, MD, Ph.D. City of Hope Medical Center
  More Information

Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT01752231     History of Changes
Other Study ID Numbers: 12050
NCI-2012-03002 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Submitted: December 12, 2012
First Posted: December 19, 2012
Last Update Posted: September 11, 2017
Last Verified: September 2017